Obesity-induced leptin resistance is a major challenge for clinical management and drug development. This study finds that FGF21 synergizes with leptin in counteracting obesity-related metabolic multimorbidity by enhancing leptin sensitivity in hepatocytes via adiponectin-induced expression of leptin receptors.